DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,872,104 Vermeulen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,872,104 Vermeulen Et Al USOO5872104A United States Patent (19) 11 Patent Number: 5,872,104 Vermeulen et al. (45) Date of Patent: Feb. 16, 1999 54) COMBINATIONS AND METHODS FOR OTHER PUBLICATIONS REDUCING ANTIMICROBAL RESISTANCE HaSobe et al., “The Synergism of Nucleoside Antibiotics 75 Inventors: Nicolaas M. J. Vermeulen Combined with Guanine 7-N-Oxide Against a Rhabdovi Woodinville: Dennis E. Schwartz rus, Infectious Hematopoietic Necrosis Virus (IHNV).” The Redmond both of Wash. s Journal of Antibiotics, vol.39, No. 9, 1291-1297, 1986. s Kovacs, et al,“Potent Effect of Trimetrexate, a Lipid 73 Assignee: Oridigm Corporation, Seattle, Wash. Soluble Antigolate, on Toxoplasma gondii.” The Journal of Infectious Diseases, vol. 155, No. 5, 1028–1032, May 1987. Touze, J.E." Actualites Et Renouveau En Therapeutique 21 Appl. No.: 364,246 Anti-Parasitaire,” La Presse Medicale, vol. 23, No. 26, 22 Filed: Dec. 27, 1994 1195–1198, Sep. 3-10, 1994. (51) Int. Cl. ............................................... A61K 31/70 Primary Examiner-Elli Peselev 52 U.S. Cl. ................................. 51429, 514/30, 514/35. Attorney, Agent, or Firm-Arnold, White & Durkee 51446 (57) ABSTRACT 58 Field of Search ................................ 514/29, 303, 30, 514/35, 46; 536/7.2 Disclosed are novel methods, combinations of agents and kits for use in killing, or inhibiting the growth of, microor 56) References Cited ganisms. Enhanced antimicrobial action is provided by using a methylation inhibitor, as exemplified by using an U.S. PATENT DOCUMENTS agent that inhibits methylation or maturation of bacterial 2,870,138 1/1959 Murray ...................................... 536/72 RNA in combination with, e.g., a macrollide lincosamide 4,497,794 2/1985 Klein et al. ............................... 514/29 streptogramin B (MLS) antibiotic. The methods and com 4,968,690 11/1990 Marquez et al. ... 514/303 positions described may be employed to reduce the resis 5,132,291 7/1992 Gruber ...................................... 574/43 tance of Susceptible microorganisms to antimicrobial agents FOREIGN PATENT DOCUMENTS and thus to treat animals or patients with infections. 0 052 705 6/1982 Germany. 132 Claims, 5 Drawing Sheets U.S. Patent Feb. 16, 1999 Sheet 1 of 5 5,872,104 P-AMNOBENZOIC ACD PTERIDINE (PABA) S-ADENOSYL DIHYDROPTEROATE METHONNE SYNTHETASE DECARBOXYLASE DIHYDROFOLATE REDUCTASE SAH HYDROLASE METHYL-B12 f HOMO Y-AMINOLEVULENIC CYSTEINE HADENOSINE ACD ADENOSNE DEAMNASE FG. A U.S. Patent Feb. 16, 1999 Sheet 2 of 5 5,872,104 ARGINNE DECARBOXYLASE DECARBOXYLATED AGMATINE SAM UREO HYDROLASE ORN THINE ORN THINE DECARBOXYLASE METHYL SPERMIDINE - ADENOSNE METHYL SPERMINE -- ADENOSNE FIG. B U.S. Patent Feb. 16, 1999 Sheet 3 of 5 5,872,104 N H N N H N N WUUNOZ WTO U.S. Patent Feb. 16, 1999 Sheet 4 of 5 5,872,104 F. s s CN O oo co r CN O y y- s U.S. Patent Feb. 16, 1999 Sheet 5 of 5 5,872,104 Wu 9NOZ WTO 5,872,104 1 2 COMBINATIONS AND METHODS FOR methods, combined compositions and kits, for use in reduc REDUCING ANTIMICROBAL RESISTANCE ing resistance to antimicrobials and antibiotics and for treating infections. The invention rests in the Surprising use BACKGROUND OF THE INVENTION of one or more inhibitors of methylation in conjunction with 1. Field of the Invention an antimicrobial agent. The combination is used to impair The present invention relates generally to the fields of the ability of a microorganism to methylate various Sub bacteria, antimicrobials and antibiotics. More particularly, it StrateS. provides novel methods, kits, and combinations of antimi AS the inventors contemplate that methylation, either at crobial agents and inhibitors, for use in reducing the resis the DNA, RNA, protein or small molecule level, plays a role tance of bacteria and other microorganisms to antimicrobial in all mechanisms of resistance of a microorganism to an agents. In particular, the invention provides for enhanced antimicrobial agent, inhibition of methylation will be widely bacterial killing using a macrollide, lincosamide and Strep applicable to reducing resistance in any given microorgan togramin B (MLS) antibiotic in combination with an agent ism or bacterium, and to treating a variety of diseases. For that inhibits methylation, as exemplified by inhibiting example, the organisms listed in Table 1 and Table 2 may be methylation or maturation of bacterial RNA. 15 targeted using the antibiotics also listed in Table 1 and Table 2. Description of the Related Art 2, amongst others, in combination with a methylation inhibi The first antibiotics were used clinically in the 1940s and tor. However, the invention is not limited to antibiotics and 195S, and their use has been increasing Significantly since to bacteria alone, and is widely applicable to all this period. Although an invaluable advance, antibiotic and microorganisms, including yeast and a variety of other antimicrobial therapy Suffers from Several problems, par pathogenic and even parasitic organisms. ticularly when Strains of various bacteria appear that are The invention therefore encompasses methods, composi resistant to antibiotics. Interestingly, bacteria resistant to tions and kits that include a methylation inhibitor capable of Streptomycin were isolated about a year after this antibiotic inhibiting any process listed in Table 1, as exemplified by the processes of antibiotic alteration, target Site alteration and was introduced (Waksman, 1945). 25 The development of antibiotic resistance is a Serious and antibiotic transport. Also, as methylation inhibitors act to life-threatening event of worldwide importance. For alter gene expression and protein Synthesis, the invention example, Strains of StaphylococcuS are known that are includes methylation inhibitors that prevent the by-pass of immune to all antibiotics except one (Travis, 1994). Such antibiotic Sensitive-steps, prevent an increase in the amount bacteria often cause fatal hospital infections. Among other of an inhibited enzyme, prevent the production of an alter drug resistant organisms are: pneumococci that cause pneu native endogenous or exogenous product, and prevent the monia and meningitis, Cryptosporidium and E. coli that production of a metabolite that antagonizes the action of cause diarrhea, and enterococci that cause blood-stream, inhibitor. Surgical wound and urinary tract infections (Berkelman et. One particular example of the applicability of the inven al., 1994). 35 tion is in providing methods and combinations for use in Davies (1986) described seven basic biochemical mecha reducing the resistance of bacteria to macrollide, nisms for naturally-occurring antibiotic resistance: (1) alter lincosamide, and streptogramin B (MLS) antibiotics, or in ation (inactivation) of the antibiotic; (2) alteration of the enhancing the Sensitivity of Susceptible Strains to Such target site; (3) blockage in the transport of the antibiotic; (4) antibiotics. In this case, the inhibitor will primarily inhibit by-pass of the antibiotic Sensitive-step (replacement); (5) 40 methylation of bacterial rRNA, thus rendering the bacterium increase in the level of the inhibited enzyme (titration of susceptible to antibiotic rRNA binding and allowing bacte drug), (6) Sparing the antibiotic-sensitive step by endog rial protein synthesis to be inhibited. enous or exogenous product; and (7) production of a The various embodiments of the invention include metabolite that antagonizes action of inhibitor. methods, combined compositions and kits for reducing the Certain bacteria become resistant to antibiotics by utiliz 45 resistance of a microorganism to an antimicrobial agent, as ing ribosomal mutations (Cunliffe, 1990), although some exemplified by reducing the antibiotic resistance of an reports have stated that this type of resistance is of doubtful MLS-susceptible bacterium to an MLS antibiotic. Also clinical significance (Spratt, 1994). Ribosomal mutations provided are methods, compositions and therapeutic kits for result in bacterial resistance to macrollide, lincosamide and killing microorganisms, Such as bacteria, and particularly, streptogramin B (MLS) antibiotics, as has been observed in 50 MLS-susceptible bacteria; and methods for treating infec the resistance of various Staphylococcus, Streptococcus, tions and diseases caused by microorganisms, including Enterococcus, Bacillus and Mycoplasma Strains to important treating MLS-Susceptible bacterial infections and diseases. antibiotics Such as erythromycin (LeClercq & Courvalin, By way of example only, certain infections that may be 1991). treated using the invention are listed in Table 3. The induction of erythromycin resistance generally leads 55 To reduce the resistance of a microorganism to an anti to bacterial strains that express rRNA which does not bind microbial agent, as exemplified by reducing the resistance of to this type of antibiotic. Mainly, erythromycin resistance is a bacterium to an antibiotic, or to kill a microorganism or due to the induction by macrollides of a methylase protein, bacterium, one would generally contact the microorganism which catalyzes the methylation of the binding site of or bacterium with an effective amount of the antibiotic or erythromycin on the rRNA, thus preventing antibiotic bind 60 antimicrobial agent in combination with an amount of a ing. Despite intensive Studies in this area, there remains few, Second agent effective to inhibit methylation in the micro if any, practical proposals as to how bacterial resistance to organism or bacterium. In terms of killing or reducing the MLS antibiotics
Load more

Recommended publications
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Maxaquin® Lomefloxacin Hydrochloride Tablets to Reduce The
    Maxaquin® lomefloxacin hydrochloride tablets To reduce the development of drug-resistant bacteria and maintain the effectiveness of Maxaquin and other antibacterial drugs, Maxaquin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Maxaquin (lomefloxacin HCl) is a synthetic broad-spectrum antimicrobial agent for oral administration. Lomefloxacin HCl, a difluoroquinolone, is the monohydrochloride salt of (±)-1-ethyl-6, 8-difluoro-1, 4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid. Its empirical formula is C17H19F2N3O3·HCl, and its structural formula is: Lomefloxacin HCl is a white to pale yellow powder with a molecular weight of 387.8. It is slightly soluble in water and practically insoluble in alcohol. Lomefloxacin HCl is stable to heat and moisture but is sensitive to light in dilute aqueous solution. Maxaquin is available as a film-coated tablet formulation containing 400 mg of lomefloxacin base, present as the hydrochloride salt. The base content of the hydrochloride salt is 90.6%. The inactive ingredients are carboxymethylcellulose calcium, hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, polyethylene glycol, polyoxyl 40 stearate, and titanium dioxide. CLINICAL PHARMACOLOGY Pharmacokinetics in healthy volunteers: In 6 fasting healthy male volunteers, approximately 95% to 98% of a single oral dose of lomefloxacin was absorbed. Absorption was rapid following single doses of 200 and 400 mg (Tmax 0.8 to 1.4 hours). Mean
    [Show full text]
  • Gene-Drug Interactions and the Evolution of Antibiotic Resistance
    Gene-Drug Interactions and the Evolution of Antibiotic Resistance The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Palmer, Adam Christopher. 2012. Gene-Drug Interactions and the Evolution of Antibiotic Resistance. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436292 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA © - Adam Christopher Palmer All rights reserved. Professor Roy Kishony Adam Christopher Palmer Gene-drug interactions and the evolution of antibiotic resistance Abstract The evolution of antibiotic resistance is shaped by interactions between genes, the chemical environment, and an antibiotic's mechanism of action. This thesis explores these interactions with experiments, theory, and analysis, seeking a mechanistic understanding of how different interactions between genes and drugs can enhance or constrain the evolution of antibiotic resistance. Chapter 1 investigates the effects of the chemical decay of an antibiotic. Tetracycline resistant and sensitive bacteria were grown competitively in the presence of tetracycline and its decay products. Antibiotic decay did not only remove selection for resistance, but long- lived decay products favored tetracycline sensitivity by inducing costly drug efflux pumps in the resistant strain. Selection against resistance by antibiotic-related compounds may contribute to the coexistence of drug-sensitive and resistant bacteria in nature. Chapter 2 investigates how genetic interactions can favor particular combinations of resistance-conferring mutations.
    [Show full text]
  • A Systematic Review of Randomised Clinical Trials for Oral Antibiotic Treatment of Acute Pyelonephritis
    European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:2285–2291 https://doi.org/10.1007/s10096-018-3371-y ORIGINAL ARTICLE A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis Jonathan W. S. Cattrall1 & Alyss V. Robinson1 & Andrew Kirby1,2 Received: 30 May 2018 /Accepted: 28 August 2018 /Published online: 6 September 2018 # The Author(s) 2018 Abstract There is increasing resistance to the oral antibiotics currently recommended for the treatment of pyelonephritis, and increased healthcare costs are associated with the reliance on alternative intravenous agents. We, therefore, performed a systematic review of randomised controlled trials to determine the clinical efficacy and safety of oral antibiotics for the treatment of pyelonephritis in adults. A search of four major medical databases (MEDLINE, Embase+ Embase classic, CENTRAL and Cochrane Database for Systematic Reviews) in addition to manual reference searching of relevant reviews was conducted. Clinical cure and adverse event rates were reported, and trial quality and bias were assessed. A total of 277 studies were reviewed; five studies matched all eligibility criteria and were included. Antibiotics included were cefaclor, ciprofloxacin, gatifloxacin, levofloxacin, lomefloxacin, loracarbef, norfloxacin, rufloxacin and trimethoprim-sulfamethoxazole. In included studies, the clinical success of the outpatient treatment of pyelonephritis by cefaclor, ciprofloxacin and norfloxacin at 4 to 6 weeks was comparable at between 83 to 95%. Relatively high rates of adverse events were noted in a trial of ciprofloxacin (24%) and trimethoprim-sulfamethoxazole (33%). Significant heterogeneity between all aspects of the trial designs was identified, with all studies having a potential for bias. This review demonstrates a need for high-quality clinical trials into the oral antibiotic treatment of pyelonephritis, with more consistent designs and reporting of outcomes.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmacology-2/ Dr
    1 Pharmacology-2/ Dr. Y. Abusamra Pharmacology-2 Quinolones, trimethoprim & sulfonamides Dr. Yousef Abdel - Kareem Abusamra Faculty of Pharmacy Philadelphia University 2 3 LEARNING OUTCOMES After completing studying this chapter, the student should be able to: Classify the drugs into subgroups such as quinolones and sulfonamides. Recognize the bacterial spectrum of all these antibiotic and antibacterial groups. Summarize the most remarkable pharmacokinetic features of these drugs. Numerate the most important side effects associated with these agents. Select the antibiotic of choice to be used in certain infections, as associated with the patient status including comorbidity, the species of bacteria causing the infection and concurrently prescribed drugs. Reason some remarkable clinical considerations related to the use or contraindication or precaution of a certain drug. Illustrate the mechanism of action of each of these drugs. • Following synthesis of na lidixic a c id in the early 1960s, continued modification of the quinolone nucleus expanded the spectrum of activity, improved pharmacokinetics, and stabilized compounds against common mechanisms of resistance. • Overuse resulted in rising rates of resistance in gram-negative and gram-positive organisms, increased frequency of Clostridium difficile infections, and identification of numerous tough adverse effects. • Consequently, these agents have been relegated to second-line options for various indications. 4 Pharmacology-2/ Dr. Y. Abusamra Only will be mentioned here 5 Pharmacology-2/ Dr. Y. Abusamra Most bacterial species maintain two distinct type II topoisomerases that assist with deoxyribonucleic acid Topoisomerases: Supercoiling Unwinding (DNA) replication: . DNA gyrase {supercoiling} and . Topoisomerase IV {Unwinding}. Following cell wall entry through porin channels, fluoroquinolones bind to these enzymes and interfere with DNA ligation.
    [Show full text]
  • Antibacterial and Pharmacological Evaluation of Fluoroquinolones: a Chemoinformatics Approach
    eISSN 2234-0742 Genomics Inform 2018;16(3):44-51 G&I Genomics & Informatics https://doi.org/10.5808/GI.2018.16.3.44 ORIGINAL ARTICLE Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach Damini Sood1, Neeraj Kumar1, Aarushi Singh1, Meena Kishore Sakharkar2, Vartika Tomar1, Ramesh Chandra1,3* 1Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India, 2College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon S7N543, Canada, 3Dr. B. R. Ambedkar Centre for Biomedical Research University of Delhi, Delhi 110007, India Fluoroquinolone (FQ) antibiotics are an important class of synthetic antibacterial agents. These are the most extensively used drugs for treating bacterial infections in the field of both human and veterinary medicine. Herein, the antibacterial and pharmacological properties of four fluoroquinolones: lomefloxacin, norfloxacin, ciprofloxacin, and ofloxacin have been studied. The objective of this study was to analyze the antibacterial characteristics of the different fluoroquinolones. Also, the pharmacological properties of the compounds including the Lipinski rule of five, absorption, distribution, metabolism, and excretion, LD50, drug likeliness, and toxicity were evaluated. We found that among all four FQ molecules, ofloxacin showed the highest antibacterial activity through in silico assays with a strong interaction (‒38.52 kJ/mol) with the antibacterial target protein (topoisomerase-II DNA gyrase enzyme). The pharmacological and pharmacokinetic analysis also showed that the compounds ciprofloxacin, ofloxacin, lomefloxacin and norfloxacin have good pharmacological properties. Notably, ofloxacin was found to possess an IGC50 (concentration needed to inhibit 50% growth) value of 0.286 μg/L against the Tetrahymena pyriformis protozoa. It also tested negative for the Ames toxicity test, showing its non-carcinogenic character.
    [Show full text]
  • THE EFFECTS of SELECTED ANTIBIOTICS on NITROGEN UPTAKE by Spirodela Punctata
    THE EFFECTS OF SELECTED ANTIBIOTICS ON NITROGEN UPTAKE BY Spirodela punctata By Cory M. Jones A Thesis Presented to The Faculty of Humboldt State University In Partial Fulfillment Of the Requirements for the Degree Master of Science In Natural Resources: Wastewater Utilization Program February, 2010 ABSTRACT The Effects of Selected Antibiotics on Nitrogen Uptake by Spirodela punctata Cory M. Jones The purpose of this study was to determine the effects of nitrogenous compound removal by the aquatic macrophyte, Spirodela punctata, when exposed to three selected antibiotics. Recent research has shown that certain antibiotics target the chloroplasts of aquatic species such as Lemna and Myriophyllum. Studies have demonstrated antibiotic toxicity to Lemna gibba at concentrations as low as 10 µg/L. Meanwhile, antibiotic concentrations in domestic wastewater lie in the nanogram to microgram range with an average of approximately 50 µg/L. In this study, Spirodela punctata was grown in a mineral salts medium containing the antibiotics chlortetracycline, lomefloxacin, and sulfamethoxazole in concentrations ranging from 10 µg/L to 300 µg/L. Fronds were allowed to grow in the medium for seven, fourteen, and twenty-one day periods. Following the growth periods, the medium was analyzed for nitrate and total nitrogen concentrations. Dry weights of fronds were taken and the dried plant material was analyzed for Total Kjeldahl Nitrogen (TKN) content. Effective concentrations (EC25 and EC50) that impacted total nitrogen and nitrate removal from the growth medium as well as dry weights and Total Kjeldahl Nitrogen of the plant tissue were calculated. Of the antibiotics tested, chlortetracycline had the most iii significant responses.
    [Show full text]